dc.contributor.author | Jaoko, Walter | |
dc.contributor.author | Vardas, E | |
dc.contributor.author | Panayotakopoulos, G | |
dc.contributor.author | Fast, P | |
dc.contributor.author | Schmidt, C | |
dc.contributor.author | Gilmour, J | |
dc.date.accessioned | 2013-02-14T08:42:53Z | |
dc.date.available | 2013-02-14T08:42:53Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Science direct | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/9847 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/17250931 | |
dc.description.abstract | Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk
volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of
25 overlapping CD8+ T cell epitopes (HIVA).
Methods: These studies compared intramuscular, subcutaneous, and intradermal MVA at dosage levels ranging from 5×106–2.5×108 pfu.
In Study IAVI-010, DNA vaccine was given as a prime at months 0 and 1, followed by MVA as a boost at months 5 and 8. In Study IAVI-011,
MVA alone was given at months 0 and 2. Regular safety monitoring was performed. Immunogenicity was measured by the interferon (IFN)-
ELISPOT assay on peripheral blood mononuclear cells (PBMC).
Results: No serious adverse events were attributed to either vaccine; most adverse events were mild or moderate, although MVA resulted in
some severe local reactions. Five vaccine recipients had at least one positive IFN- ELISPOT response, but none were sustained.
Conclusion: This HIV-1 vaccine candidate was in general safe and well-tolerated. Local reactions were common, but tolerable. Detectable
immune responses were infrequent | en |
dc.language.iso | en | en |
dc.subject | Prophylactic HIV-1 vaccine; | en |
dc.subject | safety; | en |
dc.subject | immunogenicity; | en |
dc.subject | prime-boost | en |
dc.subject | MVA (modified vaccinia virus Ankara); | en |
dc.subject | DNA vaccine | en |
dc.title | Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming | en |
dc.title.alternative | Effects of dosage and route on safety and immunogenicity | en |
dc.type | Article | en |